The why, what, who and when of B cell depletion in systemic lupus erythematosus: Biological rationale, patient stratification and evolving therapeutic modalities
Clicks: 2
ID: 325003
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
0.3
/100
2 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #60 of 197 articles by views in Lara D. Veeken
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 197 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Systemic lupus erythematosus (SLE) is driven by interconnected immune circuits in which B cells function as antigen-presenting cells, cytokine producers and precursors of autoantibody-secreting plasma cells. Therapeutic targeting of B cells aims to disrupt these self-reinforcing circuits rather than simply reduce autoantibody titres alone. Clinical experience with anti-CD20 monoclonal antibodies has validated B cells as therapeutic targets, while exposing key biological constraints, including incomplete tissue depletion, persistence of long-lived plasma cells, and BAFF-driven B cell repopulation. Recent advances including next-generation anti-CD20 monoclonal antibodies, bispecific T cell engagers, and chimeric antigen receptor (CAR) T cell therapies have shown promise but questions remain relating to which patients should be treated with what modality of therapy and when this should be timed within the disease course. Herein, we evaluate the current landscape of B cell targeting therapies with particular focus on patient selection, timing of therapy and type of treatment.
| Reference Key |
openalex_W7203492542
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Chris Wincup, Mariele Gatto, Marc Scherlinger, Georg Schett, Melanie Hagen |
| Journal | Lara D. Veeken |
| Year | 2026 |
| DOI |
10.1093/rheumatology/keag416
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.